References

A new serum type system in man—the Lp system

10.1111/j.1699-0463.1963.tb01808.x · 1963 · External reference

cDNA sequence of human apolipoprotein(a) is homologous to plasminogen

10.1038/330132a0 · 1987 · External reference

Genetic variants associated with Lp(a) lipoprotein level and coronary disease

10.1056/nejmoa0902604 · 2009 · External reference

Extreme lipoprotein(a) levels and improved cardiovascular risk prediction

10.1016/j.jacc.2012.12.023 · 2013 · External reference

Lipoprotein(a) as a cardiovascular risk factor: current status

10.1093/eurheartj/ehq386 · 2010 · External reference

Genetic associations with valvular calcification and aortic stenosis

10.1056/nejmoa1109034 · 2013 · External reference

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

10.1056/nejmoa1107579 · 2011 · External reference

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

10.1093/eurheartj/eht055 · 2013 · External reference

Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)

10.1016/j.amjcard.2014.05.060 · 2014 · External reference

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials

10.1016/j.jacc.2014.01.006 · 2014 · External reference

Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies

10.1016/j.jacc.2012.04.038 · 2012 · External reference

PCSK9 modulates the secretion but not the cellular uptake of Lipoprotein (a) ex vivo: an effect blunted by alirocumab

2016 · External reference